Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1681-1692

  Motta, Concettina La ^a   Sartini, Stefania ^a   Mugnaini, Laura ^a   Salerno, Silvia ^a   Simorini, Francesca ^a   Taliani, Sabrina ^a   Marini, Anna Maria ^a   Settimo, Federico Da ^a   Lavecchia, Antonio ^b   Novellino, Ettore ^b   Antonioli, Luca ^a   Fornai, Matteo ^a   Blandizzi, Corrado ^a   Tacca, Mario Del ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 ((4 OXO 4,5 DIHYDROPYRAZOLO[3,4 D]PYRIMIDIN 2YL)METHYL)PHENYL) 3 (4 (TRIFLUOROMETHYL)PHENYL)UREA; 2 (4 AMINOBENZYL) 2H PYRAZOLO[3,4 D]PYRIMIDIN 4 (5H) ONE,; 2 (4 NITROBENZYL) 2H PYRAZOLO[3,4 D]PYRIMIDIN 4 (5H) ONE; 2 ALKYLPYRAZOLO[3,4 D]PYRIMIDIN 4 ONE DERIVATIVE; 3 AMINO 1 (4 NITROBENZYL) 4 PYRAZOLECARBONITRILE; ADENOSINE DEAMINASE INHIBITOR; DEXAMETHASONE; N (4 ((4 OXO 4,5 DIHDROPYRAZOLO[3,4 D ]PYRIMIDIN 2 YL)METHYL)PHENYL)ARYLAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; X RAY ANALYSIS;

ADENOSINE DEAMINASE; ANIMALS; CATALYTIC DOMAIN; COLITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; PYRAZOLES; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349101279     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801427r     Document Type: Article

References (72)

1. Cristalli, G.; Costanzi, S.; Lambertucci, C.; Lupidi, G.; Vittori, S.; Volpini, R.; Campioni, E. Adenosine Deaminase: Functional Implications and Different Classes of Inhibitors. Med.Res.Rev. 2001, 21, 105-128.
2. Yegutkin, G. G. Nucleotide- and Nucleoside-Converting Ectoenzymes: Important Modulators of Purinergic Signalling Cascade. Biochim. Biophys. Acta, Mol. Cell Res. 2008, 1783, 673-694.
3. Franco, R.; Mallol, J.; Casado, V.; Lluis, C.; Canela, E. I.; Saura, C.; Blanco, J.; Ciruela, F. Ecto-Adenosine Deaminase: An Ecto-Enzyme and a Costimulatory Protein Acting on a Variety of Cell Surface Receptors. Drug Dev. Res. 1998, 45, 261-268.
4. Franco, R.; Valenzuela, A.; Lluis, C.; Blanco, J. Enzymatic and Extraenzymatic Role of Ecto-Adenosine Deaminase in Lymphocytes. Immunol. Rev. 1998, 161, 27-42.
5. Aldrich, M. B.; Blackburn, M. R.; Kellems, R. E. The Importance of Adenosine Deaminase for Lymphocyte Development and Function. Biochem.Riophys.Res.Commun. 2000, 272, 311-315.
6. Chen, T.; Smyth, T.; Abbott, C. A. CD26. J. Biol. Regul. Homeostatic Agents 2004, 181, 47-54.
7. Blackburn, M. R.; Kellems, R. E. Adenosine Deaminase Deficiency: Metabolic Basis of Immune Deficiency and Pulmonary Inflammation. Adv. Immunol. 2005, 86, 1-41.
8. Hershfield, M. S. New Insights into Adenosine-Receptor-Mediated Immunosuppression and the Role of Adenosine in Causing the Immunodeficiency Associated with Adenosine Deaminase Deficiency. Eur. J. Immunol. 2005, 35, 25-30.
9. Resta, R.; Thompson, L. F. SCID: The Role of Adenosine Deaminase Deficiency. Immunol. Today 1997, 18, 371-374.
10. Hershfield, M. S. Adenosine Deaminase Deficiency: Clinical Expression, Molecular Basis, and Therapy. Semin Hematol. 1998, 35, 291-298.
11. Sauter, C.; Lamanna, N.; Weiss, M. A. Pentostatin in Chronic Lymphocytic Leukemia. Expert Opin. Drug Metab. Toxicol 2008, 4, 1217-1222.
12. Honma, Y. A Novel Therapeutic Strategy Against Monocytic Leukemia with Deoxyadenosine Analogs and Adenosine Deaminase Inhibitors. Leuk. Lymphoma 2001, 42, 953-962.
13. Robak, T.; Korycka, A.; Kasznicki, M.; Wrzesien-Kus, A.; Smolewski, P. Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications. Curr. Cancer Drug Targets 2005, 5, 421-444.
14. Kose, K.; Utas, S.; Yazici, C.; Akdas, A.; Kelestimur, F. Effect of Propylthiouracil on Adenosine Deaminase Activity and Thyroid Function in Patients with Psoriasis. Br. J. Dermatol. 2001, 144, 1121-1126.
15. Cronstein, B. N. Adenosine: An Endogenous Anti-Inflammatory Agent. J. Awl. Physiol. 1994, 76, 5-13.
16. Ohta, A.; Sitkovsky, M. Role of G-Protein-Coupled Adenosine Receptors in Down-Regulation of Inflammation and Protection from Tissue Damage. Nature 2001, 414, 916-920.
17. Hasko, G.; Deitch, E. A.; Szabo, C.; Nemeth, Z. H.; Vizi, E. S. Adenosine: A Potential Mediator of Immunosuppression in Multiple Organ Failure. Curr. Opin. Pharmacol. 2002, 2, 440-444.
18. Hasko, G.; Cronstein, B. N. Adenosine: An Endogenous Regulator of Innate Immunity. Trends Immunol. 2004, 25, 33-39.
19. Cha, S.; Agarwal, R. P.; Parks, R. E., Jr. Thigh-Binding Inhibitors. II. Non-Steady-State Nature of Inhibition of Milk Xantine Oxidase by Allopurinol and Alloxanthine and of Human Erythrocytic Adenosine Deaminase by Coformicin. Biochem. Pharmacol. 1975, 24, 2187-2197.
20. Agarwal, R. P.; Spector, T.; Parks, R. E., Jr. Thigh-Binding Inhibitors. IV. Inhibition of Adenosine Deaminase by Various Inhibitors. Biochem. Pharmacol. 1977, 26, 359-367.
21. Schaeffer, H. J.; Schwender, C. F. Enzyme Inhibitors. 26. Bridging Hydrophobic and Hydrophilic Regions of Adenosine Deaminase with Some 9-(2-Hydroxy-3-alkyl)adenines. J. Med. Chem. 1974, 17, 6-8.
22. Da Settimo, F.; Primofiore, G.; La Motta, C.; Taliani, S.; Simorini, F.; Marini, A. M.; Mugnaini, L.; Lavecchia, A.; Novellino, E.; Tuscano, D.; Martini, C. Novel, Highly Potent Adenosine Deaminase Inhibitors Containing the Pyrazolo[3,4-d]pyrimidine Ring System. Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 2005, 48, 5162-5174.
23. Antonioli, L.; Fornai, M.; Colucci, R.; Ghisu, N.; Da Settimo, F.; Natale, G.; Kastsiuchenka, O.; Duranti, E.; Virdis, A.; Vassalle, C.; La Motta, C.; Mugnaini, L.; Breschi, M. C.; Blandizzi, C.; Del Tacca, M. Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. J. Pharmacol. Exp. Ther. 2007, 322, 435-442.
24. Terasaka, T.; Nakanishi, I.; Nakamura, K.; Eikyu, Y.; Kinoshita, T.; Nishio, N.; Sato, A.; Kuno, M.; Seki, N.; Sakane, K. Structure-Based de Novo Design of Non-Nucleoside Adenosine Deaminase Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1115-1118.
25. Terasaka, T.; Kinoshita, T.; Kuno, M.; Nakanishi, I. A Highly Potent Non-Nucleoside Adenosine Deaminase Inhibitor: Efficient Drug Discovery by Intentional Lead Hybridization. J. Am. Chem. Soc. 2004, 126, 34-35.
26. Terasaka, T.; Okumura, H.; Tsuji, K.; Kato, T.; Nakanishi, I.; Kinoshita, T.; Kato, Y.; Kuno, M.; Seki, N.; Naoe, Y.; Inoue, T.; Tanaka, K.; Nakamura, K. Structure-Based Design and Synthesis of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors. J. Med. Chem. 2004, 47, 2728-2731.
27. Terasaka, T.; Kinoshita, T.; Kuno, M.; Seki, N.; Tanaka, K.; Nakanishi, I. Structure-Based Design, Synthesis, and Structure-Activity Relationship Studies of Novel Non-Nucleoside Adenosine Deaminase Inhibitors. J. Med. Chem. 2004, 47, 3730-3743.
28. Terasaka, T.; Tsuji, K.; Kato, T.; Nakanishi, I.; Kinoshita, T.; Kato, Y.; Kuno, M.; Inoue, T.; Tanaka, K.; Nakamura, K. Rational Design of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors: Predicting Enzyme Conformational Change and Metabolism. J. Med. Chem. 2005, 48, 4750-4753.
29. Siegmund, B.; Rieder, F.; Albrich, S.; Wolf, K.; Bidlingmaier, C.; Firestein, G. S.; Boyle, D.; Lehr, H. A.; Loher, F.; Hartmann, G.; Endres, S.; Eigler, A. Adenosine Kinase Inhibitor GP515 Improves Experimental Colitis in Mice. J. Pharmacol Exp. Ther. 2001, 296, 99-105.
30. Robak, T. Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues: Facts and Controversies. Drugs Aging 2005, 22, 983-1012.
31. Sauter, C.; Lamanna, N.; Weiss, M. A. Pentostatin in Chronic Lymphocytic Leukemia. Expert Opin Drug Metab. Toxicol. 2008, 4, 1217-22.
32. Wilson, D. K.; Rudolph, F. B.; Quiocho, F. A. Atomic Structure of Adenosine Deaminase Complexed with a Transition State Analog: Understanding Catalysis and Immunodeficiency Mutation. Science 1991, 252, 1278-1284.
33. Wilson, D. K.; Quiocho, F. A. A Pre-Transition-State Mimic of an Enzyme: X-ray Structure of Adenosine Deaminase with Bound 1-Deazaadenosine and Zinc Activated Water. Biochemistry 1993, 32, 1689-1694.
34. Wang, Z.; Quiocho, F. A. Complexes of Adenosine Deaminase with Two Potent Inhibitors: X-ray Structures in Four Independent Molecules at pH of Maximum Activity. Biochemistry 1998, 37, 8314-8324.
35. Kinoshita, T.; Nakanishi, I.; Terasaka, T.; Kuno, M.; Seki, N.; Warizaya, M.; Matsumura, H.; Inoue, T.; Takano, K.; Adachi, H.; Mori, Y.; Fujii, T. Structural Basis of Compound Recognition by Adenosine Deaminase. Biochemistry 2005, 44, 10562-10569.
36. Kinoshita, T.; Tada, T.; Nakanishi, I. Conformational Change of Adenosine Deaminase during Ligand-Exchange in a Crystal. Biochem. Biophys. Res. Commun. 2008, 373, 53-57.
37. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
38. Kinoshita, T.; Nishio, N.; Sato, A.; Murata, M. Crystallization and Preliminary Analysis of Bovine Adenosine Deaminase. Acta Crystallogr. 1999, D55, 2031-2032.
39. Kinoshita, T.; Nishio, N.; Nakanishi, I.; Sato, A.; Fujii, T. Crystal Structure of Bovine Adenosine Deaminase Complexed with 6-Hydroxyl-1,6- dihydropurine Riboside. Acta Crystallogr. 2003, D59, 299-303.
40. GOLD, version 4.0; CCDC Software Limited: Cambridge, U.K., 2008.
41. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997, 267, 727-748.
42. Schulz-Gasch, T.; Stahl, M. Binding Site Characteristics in Structure-Based Virtual Screening: Evaluation of Current Docking Tools. J. Mol. Model. 2003, 9, 47-57.
43. Wang, R.; Lu, Y.; Wang, S. Comparative Evaluation of 11 Scoring Functions for Molecular Docking. J. Med. Chem. 2003, 46, 2287-2303.
44. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative Evaluation of Eight Docking Tools for Docking and Virtual Screening Accuracy. Proteins: Struct., Funct., Bioinf. 2004, 57, 225-242.
45. Warre, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A Critical Assessment of Docking Programs and Scoring Functions. J. Med. Chem. 2006, 49, 5912-5931.
46. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved Protein-Ligand Docking Using GOLD. Proteins: Struct., Funct., Genet. 2003, 52, 609-623.
47. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical Scoring Functions: i. The Development of a Fast Empirical Scoring Function To Estimate the Binding Affinity of Ligands in Receptor Complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
48. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen Bonding Interactions of Covalently Bonded Fluorine Atoms: From Crystallographic Data to a New Angular Function in the GRID Force Field. J. Med. Chem. 2004, 47, 5114-5125.
49. Cheng, Y. C.; Prusoff, W. H. Relation Between Inhibition Constant Ki and the Concentration of Inhibitor Which Causes Fifty Percent Inhibition (IC50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
50. Nakase, H.; Okazaki, K.; Tabata, Y.; Uose, S.; Ohana, M.; Uchida, K.; Nishi, T.; Debreceni, A.; Itoh, T.; Kawanami, C.; Iwano, M.; Ikada, Y.; Chiba, T. An Oral Drug Delivery System Targeting Immune-Regulating Cells Ameliorates Mucosal Injury in Trinitrobenzene Sulfonic Acid-Induced Colitis. J. Pharmacol. Exp. Ther. 2001, 297, 1122-1128.
51. Fornai, M.; Blandizzi, C.; Antonioli, L.; Colucci, R.; Bernardini, N.; Segnani, C.; De Ponti, F.; Del Tacca, M. Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. J. Pharmacol. Exp. Ther. 2006, 317, 938-945.
52. Marquez, E.; Sanchez-Fidalgo, S.; Calvo, J. R.; de la Lastra, C. A.; Motilva, V. Acutely Administered Melatonin Is Beneficial While Chronic Melatonin Treatment Aggravates the Evolution of TNBS-Induced Colitis. J. Pineal Res. 2006, 40, 48-55.
53. Molecular Operating Environment (MOE), version 2005.06; Chemical Computing Group, Inc.: Montreal, Canada, 2005.
54. Huang, C. C.; Couch, G. S.; Pettersen, E. F.; Ferrin, T. E. Chimera: An Extensible Molecular Modelling Application Constructed Using Standard Components. Pac. Symp. Biocomput. 1996, 1, 724. (http:/www.cgl.ucsf.edu/chimera).
55. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D. H.; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER, version 9; University of California: San Francisco, CA, 2006.
56. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
57. Halgren, T. A. Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-512.
58. Halgren, T. A. Merck Molecular Force Field. II. MMFF94 van der Waals and Electrostatic Parameters for Intermolecular Interactions. J. Comput. Chem. 1996, 17, 520-552.
59. Halgren, T. A. Merck Molecular Force Field. III. Molecular Geometries and Vibrational Parameters for Intermolecular Interactions. J. Comput. Chem. 1996, 17, 553-586.
60. Halgren, T. A. Merck Molecular Force Field. IV. Conformational Energies and Geometries for MMFF94. J. Comput. Chem. 1996, 17, 587-615.
61. Halgren, T. A. Merck Molecular Force Field. V. Extension of MMFF94 Using Experimental Data, Additional Computational Data, and Empirical Rules. J. Comput. Chem. 1996, 17, 616-641.
62. Lovell, S. C.; Word, J. M.; Richardson, J. S.; Richardson, D. C. The Penultimate Rotamer Library. Proteins 2000, 40, 389-408.
63. Pang, Y. P. Novel Zinc Protein Molecular Dynamics Simulations: Steps Toward Antiangiogenesis for Cancer Treatment. J. Mol. Model. 1999, 5, 196-202.
64. Hoops, S. C.; Anderson, K. W.; Merz, K. M. J. Force Field Design for Metalloproteins. J. Am. Chem. Soc. 1991, 113, 8262-8270.
65. Ryde, U. Molecular Dynamics Simulations of Alcohol Dehydrogenase with a Four- or Five-Coordinate Catalytic Zinc Ion. Proteins 1995, 21, 40-56.
66. Lu, D. S.; Voth, G. A. Molecular Dynamics Simulations of Human Carbonic Anhydrase II: Insight into Experimental Results and the Role of Solvation. Proteins 1998, 33, 119-134.
67. Berweger, C. D.; Thiel, W.; van Gunsteren, W. F. Molecular-Dynamics Simulation of the Beta Domain of Metallothionein with a Semiempirical Treatment of the Metal Core. Proteins 2000, 41, 299-315.
68. Pang, Y. P.; Xu, K.; El Yazal, J.; Prendergast, F. G. Successful Molecular Dynamics Simulation of the Zinc-Bound Farnesyltransferase Using the Cationic Dummy Atom Approach. Protein Sci. 2000, 9, 1857-1865.
69. El Yazal, J.; Pang, Y. P. Ab Initio Calculations of Proton Dissociation Energies of Zinc Ligands: Hypothesis of Imidazolate as Zinc Ligand in Proteins. J. Phys. Chem. B 1999, 103, 8773-8779.
70. El Yazal, J.; Roe, R. R.; Pang, Y. P. Zinc's Affect on Proton Transfer between Imidazole and Acetate Predicted by ab Initio Calculations. J. Phys. Chem. B 2000, 104, 6662-6667.
71. El Yazal, J.; Pang, Y. P. Comparison of DFT, Moller-Plesset, and Coupled Cluster Calculations of the Proton Dissociation Energies of Imidazole and N-Methylacetamide in the Presence of Zinc(II). J. Mol. Struct.: THEOCHEM 2001, 545, 271-274.
72. Pang, Y. P. Successful Molecular Dynamics Simulation of Two Zinc Complexes Bridged by a Hydroxide in Phosphotriesterase Using the Cationic Dummy Atom Method. Proteins 2001, 45, 183-189.